Worthing to benefit from £200m GSK investment

PHARMACEUTICAL giant GSK has announced a series of investments totalling approximately £200 million nationally, including at its Worthing operation.

The manufacturing site in the town, as well as another in Ware, Hertfordshire, will be upgraded with state-of-the-art new equipment.

In Worthing, a new bulk sterile building and filling line will be built for the company’s leading antibiotic medicine, Augmentin, which is exported to 150 countries.

Roger Connor, GSK’s President of Global Manufacturing and Supply, said: “The establishment of the Patent Box has transformed how we see the UK as a place to invest. As a result, last year we announced we were building our first new factory in the UK for 40 years.

“The investments announced are in addition to that and will allow us to harness new technologies that have the potential to deliver a step-change in how we make medicines. These new technologies could significantly reduce costs, improve quality and enable the manufacture of medicines in weeks rather than years and I am delighted that we have been able to bring these investments to the UK.”